Pharvaris N.V.

Report azionario NasdaqGS:PHVS

Capitalizzazione di mercato: US$2.4b

Pharvaris Gestione

Criteri Gestione verificati 3/4

Pharvaris Il CEO è Berndt Axel Modig, nominato in Sep2015, e ha un mandato di 10.92 anni. la retribuzione annua totale è € 5.06M, composta da 14.7% di stipendio e 85.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.55% delle azioni della società, per un valore di $ 37.80M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.1 anni e 5.6 anni.

Informazioni chiave

Berndt Axel Modig

Amministratore delegato

€5.1m

Compenso totale

Percentuale dello stipendio del CEO14.75%
Mandato del CEO10.9yrs
Proprietà del CEO1.5%
Durata media del management5.1yrs
Durata media del Consiglio di amministrazione5.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Seeking Alpha • Aug 04

Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment

Summary Pharvaris is positioned to build a vertically integrated HAE franchise with deucrictibant in both immediate-release (IR) and extended-release (XR) forms. PHVS’s NDA for deucrictibant IR was accepted by the FDA, with a PDUFA date set for April 23, 2027, following strong Phase 3 RAPIDe-3 results. The CHAPTER-3 Phase 3 data for deucrictibant XR, expected Q3 2026, is the pivotal catalyst determining PHVS’s potential as an end-to-end HAE platform. PHVS’s premium valuation is justified by de-risked regulatory milestones, but the success of CHAPTER-3 is critical to sustaining the franchise thesis. Read the full article on Seeking Alpha
Articolo di analisi • Jun 16

Pharvaris (PHVS) Stock Could Be Far Below Fair Value After Phase 3 HAE Data

Pharvaris (NasdaqGS:PHVS) stock is in focus after the company reported detailed Phase 3 RAPIDe-3 and long-term CHAPTER-1 data for its oral hereditary angioedema therapy deucrictibant at the EAACI 2026 Congress. See our latest analysis for Pharvaris. Against this backdrop of detailed Phase 3 data and conference activity, Pharvaris stock has a 90 day share price return of 17.16% and a 1 year total shareholder return of 85.97%, suggesting building momentum as investors respond to the HAE program...
Articolo di analisi • Jul 05

Here's Why We're Watching Pharvaris' (NASDAQ:PHVS) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Mar 17

We're Hopeful That Pharvaris (NASDAQ:PHVS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Dec 29

Pharvaris: Despite 30% Decline, Still Fair At Best

Summary Pharvaris is a pre-revenue biotech company with significant cash burn and a high development burden, making it a risky investment in a high-cost capital environment. Despite positive trial data, the company's valuation remains optimistic, considering the market size and potential outstanding development costs. The current market cap of $1 billion + $900 million development burden against a $2 billion gross value capture is not a great value setup. With only $300 million in liquidity and an estimated $900 million development burden, Pharvaris also has reflexivity risks. Read the full article on Seeking Alpha
Articolo di analisi • Dec 02

Here's Why We're Not Too Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Articolo di analisi • Aug 16

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Jan 17

Pharvaris: Digging Deep For Sufficient Market Size

Summary Pharvaris is developing a molecule called Deucrictibant to treat acute hereditary angioedema (HAE) and provide prophylactic treatment. The market size for HAE is estimated to be around $2 billion, but that's digging deep and outside of the more profitable developed markets. Pharvaris has $440 million in available liquidity, including cash and a newly underwritten issue, but there is still a significant R&D burden and potential dilution in the company's future. At a $1.45 billion market cap, with outstanding burdens and a best-case market size at $2 billion according to our figures, we don't see the appeal here. Read the full article on Seeking Alpha
Articolo di analisi • Oct 09

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. Indeed, Pharvaris ( NASDAQ:PHVS...
Articolo di analisi • May 13

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Articolo di analisi • Jan 11

Companies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Articolo di analisi • Sep 26

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Sep 12

Pharvaris GAAP EPS of -€0.38

Pharvaris press release (NASDAQ:PHVS): Q2 GAAP EPS of -€0.38. Cash and cash equivalents were €201 million as of June 30, 2022, compared to €209 million as of December 31, 2021.
Seeking Alpha • Aug 22

Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate

Pharvaris N.V. (NASDAQ:PHVS) dropped ~19% in the pre-market trading Monday after the Dutch biopharma announced that the FDA verbally notified its plans to issue a clinical hold on the clinical trials of hereditary angioedema candidate PHA121. The decision is based on a review of nonclinical data, and the agency intends to offer a formal clinical hold letter within the next 30 days. A small molecule bradykinin B2-receptor antagonist, PHA121, was undergoing clinical studies in the U.S. under two Investigational New Drug (IND) applications for HAE. “We are fully committed to working closely with the FDA to address the agency’s concerns,” PHVS Chief Executive Berndt Modig remarked.
Articolo di analisi • Jun 08

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Dec 21

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Articolo di analisi • Aug 25

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Berndt Axel Modig rispetto agli utili di Pharvaris?
DataCompenso totaleStipendioUtili della società
Mar 31 2026n/an/a

-€169m

Dec 31 2025€5m€746k

-€176m

Sep 30 2025n/an/a

-€164m

Jun 30 2025n/an/a

-€168m

Mar 31 2025n/an/a

-€153m

Dec 31 2024€581k€581k

-€134m

Sep 30 2024n/an/a

-€132m

Jun 30 2024n/an/a

-€114m

Mar 31 2024n/an/a

-€106m

Dec 31 2023€532k€532k

-€101m

Sep 30 2023n/an/a

-€107m

Jun 30 2023n/an/a

-€92m

Mar 31 2023n/an/a

-€83m

Dec 31 2022€500k€500k

-€76m

Sep 30 2022n/an/a

-€49m

Jun 30 2022n/an/a

-€50m

Mar 31 2022n/an/a

-€53m

Dec 31 2021€414k€414k

-€43m

Sep 30 2021n/an/a

-€41m

Jun 30 2021n/an/a

-€38m

Mar 31 2021n/an/a

-€29m

Dec 31 2020€404k€404k

-€26m

Compensazione vs Mercato: La retribuzione totale di Berndt Axel ($USD 5.84M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 6.98M ).

Compensazione vs guadagni: La retribuzione di Berndt Axel è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Berndt Axel Modig (67 yo)

10.9yrs
Mandato
€5,061,648
Compensazione

Mr. Berndt Axel Edvard Modig, MBA, CPA, serves as Chief Executive Officer of Pharvaris B.V. since 2015 and serves as its Executive Director since September 30, 2015. Mr. Modig served as a Member of the Sup...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Berndt Axel Modig
Co-Founder10.9yrs€5.06m1.55%
$ 37.8m
Peng Lu
Presidentno dataNessun dato0.034%
$ 839.2k
David Nassif
CFO, Chief Legal Officer & Corporate Secretary2.3yrsNessun dato0.092%
$ 2.3m
Anna Nijdam
Head of Strategic Finance & Principal Accounting Officer6.6yrsNessun dato0.066%
$ 1.6m
Stefan Abele
Chief Technology Operations Officer2.8yrsNessun dato0.050%
$ 1.2m
Annick Deschoolmeester
Chief Human Resources Officer3.9yrsNessun dato0.13%
$ 3.2m
Anne Lesage
Chief Early Development Officer11.6yrsNessun dato0.17%
$ 4.1m
Wim Souverijns
Chief Commercial Officer5.1yrsNessun dato0.065%
$ 1.6m
Maryann Cimino
Director of Corporate Relationsno dataNessun datoNessun dato
5.1yrs
Durata media
55.5yo
Età media

Gestione esperta: Il team dirigenziale di PHVS è esperto e expertise (durata media dell'incarico 5.1 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Berndt Axel Modig
Co-Founder10.9yrs€5.06m1.55%
$ 37.8m
Robert Glassman
Independent Non-Executive Director5.6yrs€371.91k0.015%
$ 366.7k
David Meeker
Independent Non-Executive Chair5.6yrs€406.03k0.093%
$ 2.3m
Hans J. G. C. Schikan
Independent & Non-Executive Vice Chairman7yrs€376.50k0.45%
$ 11.0m
Elisabeth Bjork
Non-Executive Director4.7yrs€374.22k0.014%
$ 337.4k
Viviane Monges
Independent Non-Executive Director5.2yrs€384.23k0%
$ 0
5.6yrs
Durata media
66yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PHVS sono considerati esperti (durata media dell'incarico 5.6 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/08/10 07:57
Prezzo dell'azione a fine giornata2026/08/10 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Pharvaris N.V. è coperta da 19 analisti. 12 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Tazeen AhmadBofA Global Research
Steven SeedhouseCantor Fitzgerald & Co.
Jonathan WollebenCitizens JMP Securities, LLC